Balyasny Asset Management
GPCR icon

Balyasny Asset Management’s Structure Therapeutics GPCR Stock Holding History

Balyasny Asset Management’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-304,934
Closed -$14.7M – 3199
2026
Q1 		$14.7M Buy
304,934
+88,735
+41% +$6.07M 0.02% 835
2025
Q4 		$15M Sell
216,199
-245,354
-53% -$10M 0.02% 859
2025
Q3 		$12.9M Buy
+461,553
New +$9.19M 0.02% 925
2025
Q2 		– Sell
-202,483
Closed -$3.5M – 3022
2025
Q1 		$3.5M Buy
+202,483
New +$4.96M 0.01% 1423
2023
Q4 		– Sell
-13,430
Closed -$677K – 2643
2023
Q3 		$677K Buy
+13,430
New +$433K ﹤0.01% 1665

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Balyasny Asset Management's GPCR Position: Q2 2026 in Review

Balyasny Asset Management sold out of Structure Therapeutics (GPCR) in Q2 2026, closing a stake of 304,934 shares — an estimated $14.7M sold.

Balyasny Asset Management first reported a position in GPCR in Q3 2023 and held it in 5 quarters. The position peaked at $15M in Q4 2025. 191 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • Balyasny Asset Management reported no remaining Structure Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Balyasny Asset Management sold 304,934 Structure Therapeutics shares in Q2 2026, an estimated $14.7M.
  • Balyasny Asset Management first reported a position in Structure Therapeutics in Q3 2023 and held it in 5 quarters.
  • Balyasny Asset Management's Structure Therapeutics position peaked at $15M in Q4 2025.
  • 191 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.